AptarGroup, Inc. provides a range of packaging, dispensing, and sealing solutions primarily for the beauty, personal care, home care, prescription drug, consumer health care, injectable, and food and beverage markets. The company operates through three segments: Pharma, Beauty + Home, and Food + Beverage. The Pharma segment provides pumps for nasal allergy treatments; and metered dose inhaler valves for respiratory ailments, such as asthma and chronic obstructive pulmonary diseases in pharmaceutical market; elastomer for injectable primary packaging components; and active packaging products. The Beauty + Home segment primarily sells pumps, closures, aerosol valves, accessories, and sealing solutions to the personal care and home care markets; and pumps and decorative components to the beauty market. The Food + Beverage segment offers dispensing and non-dispensing closures, elastomeric flow control components, spray pumps, and aerosol valves to the food and beverage markets. The company sells its products through own sales force, as well as independent representatives and distributors in Asia, Europe, Latin America, and North America. AptarGroup, Inc. has a strategic partnership with PureCycle Technologies LLC to develop ultra-pure recycled polypropylene into dispensing applications; and a collaboration with Sonmol for developing a digital therapies and services platform targeting respiratory and other diseases. The company was incorporated in 1992 and is headquartered in Crystal Lake, Illinois.
IPO Year:
Exchange: NYSE
Website: aptar.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/20/2026 | $144.00 | Equal Weight → Overweight | Wells Fargo |
| 1/6/2026 | $133.00 | Overweight → Equal Weight | Wells Fargo |
| 11/3/2025 | Outperform → Mkt Perform | William Blair | |
| 9/4/2025 | $220.00 | Overweight | KeyBanc Capital Markets |
| 1/7/2025 | $200.00 | Outperform | Raymond James |
| 1/6/2025 | $173.00 | Buy → Neutral | BofA Securities |
| 10/14/2024 | $155.00 → $215.00 | Hold → Buy | Jefferies |
| 4/29/2024 | Mkt Perform → Outperform | William Blair | |
| 1/3/2024 | $125.00 → $150.00 | Neutral → Outperform | Robert W. Baird |
| 1/20/2022 | $150.00 → $126.00 | Equal-Weight | Morgan Stanley |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - APTARGROUP, INC. (0000896622) (Issuer)
4 - APTARGROUP, INC. (0000896622) (Issuer)
4 - APTARGROUP, INC. (0000896622) (Issuer)
4 - APTARGROUP, INC. (0000896622) (Issuer)
4 - APTARGROUP, INC. (0000896622) (Issuer)
4 - APTARGROUP, INC. (0000896622) (Issuer)
4 - APTARGROUP, INC. (0000896622) (Issuer)
4 - APTARGROUP, INC. (0000896622) (Issuer)
4 - APTARGROUP, INC. (0000896622) (Issuer)
4 - APTARGROUP, INC. (0000896622) (Issuer)
SD - APTARGROUP, INC. (0000896622) (Filer)
8-K - APTARGROUP, INC. (0000896622) (Filer)
8-K - APTARGROUP, INC. (0000896622) (Filer)
10-Q - APTARGROUP, INC. (0000896622) (Filer)
8-K - APTARGROUP, INC. (0000896622) (Filer)
DEFA14A - APTARGROUP, INC. (0000896622) (Filer)
DEF 14A - APTARGROUP, INC. (0000896622) (Filer)
SCHEDULE 13G/A - APTARGROUP, INC. (0000896622) (Subject)
8-K - APTARGROUP, INC. (0000896622) (Filer)
SCHEDULE 13G/A - APTARGROUP, INC. (0000896622) (Subject)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Wells Fargo upgraded AptarGroup from Equal Weight to Overweight and set a new price target of $144.00
Wells Fargo downgraded AptarGroup from Overweight to Equal Weight and set a new price target of $133.00
William Blair downgraded AptarGroup from Outperform to Mkt Perform
KeyBanc Capital Markets initiated coverage of AptarGroup with a rating of Overweight and set a new price target of $220.00
Raymond James initiated coverage of AptarGroup with a rating of Outperform and set a new price target of $200.00
BofA Securities downgraded AptarGroup from Buy to Neutral and set a new price target of $173.00
Jefferies upgraded AptarGroup from Hold to Buy and set a new price target of $215.00 from $155.00 previously
William Blair upgraded AptarGroup from Mkt Perform to Outperform
Robert W. Baird upgraded AptarGroup from Neutral to Outperform and set a new price target of $150.00 from $125.00 previously
Morgan Stanley reiterated coverage of AptarGroup with a rating of Equal-Weight and set a new price target of $126.00 from $150.00 previously
Fastest customizable press release news feed in the world
Recognized for Continued Supply Chain Collaboration AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, was named a CDP Supplier Engagement Leader, for the sixth consecutive year. This assessment, based on information reported within the 2025 CDP reporting cycle, highlights companies that are engaging their suppliers on climate change and supporting efforts to address emissions throughout the value chain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260602301467/en/Aptar is Named a CDP Supplier Engagement Leader for the Sixth Consecutive Year By
AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced that it will present at two upcoming investor conferences: Jefferies Global Healthcare Conference in New York, NY on Wednesday, June 3, 2026. Vanessa Kanu, Executive Vice President and CFO, will present at 12:45 p.m. Eastern Standard Time. Wells Fargo Industrials and Materials Conference in Chicago, IL on Tuesday, June 9, 2026. Vanessa Kanu, Executive Vice President and CFO, will present at 1:45 p.m. Eastern Standard Time. A live audio webcast and presentation materials will be available in the "Investors" section of the Company's websi
Innovation wins 2026 DIELINE Award with Clarins Total Eye Lift for ‘Sustainable Design – Health, Body & Beauty' AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today highlighted how its patented, high performance airless dispensing innovation is enabling prestige beauty brands to advance sustainability without compromising performance or luxury. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260506201869/en/Aptar Advances Sustainability Features in Luxury Packaging through Patented Reloadable Airless Innovation with Clarins. Through a long‑stan
AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery and consumer product dispensing, dosing and protection technologies, today reported the following first quarter results for the period ended March 31, 2026, as compared to the corresponding period of the last fiscal year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430601030/en/Aptar Reports First Quarter 2026 Results First Quarter 2026 Highlights (Compared to the prior year quarter; see Non-GAAP section for full definitions; see reconciliation for Non-GAAP measures) Reported sales increased 11% and core sales were flat Reported net income decreased 8% t
Features company's patented SimpliSqueeze® valve for ready-to-dispense convenience, focused on reducing mess and drips AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced it has launched a new line of inverted lidless dispensing closures for the beauty and personal care markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427887104/en/Aptar's Inverted Lidless Dispensing Closures Aptar's inverted lidless closures help eliminate the need for separate lids while allowing for an inverted, ready-to-dispense packaging format that he
AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, including dosing and protection technologies, and consumer product dispensing, today announced that the Board declared a quarterly cash dividend of $0.48 per share. The payment date is May 27, 2026, to stockholders of record as of May 6, 2026. As previously announced, Aptar will hold a conference call on Friday, May 1, 2026, at 8:00 a.m. Central Time to discuss the Company's first quarter results for 2026. The call will last approximately one hour. Interested parties are invited to listen to a live webcast by visiting the Investors page at www.aptar.com. A replay of the conference call can also be accessed for a limited time o
AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, including dosing and protection technologies, and consumer product dispensing, announced today that has been named one of America's Climate Leaders by USA Today for the fourth consecutive year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422480656/en/Aptar Recognized as One of America's Climate Leaders by USA Today for the Fourth Consecutive Year (Logo used with permission from Statista) "This recognition reflects the dedication of our teams worldwide and our long-term commitment to sustainability and climate action," said Beth Holland, Chief Sustainability Off
CINCINNATI, April 08, 2026 (GLOBE NEWSWIRE) -- Aptar Digital Health, a global leader in digital health solutions enhancing the patient experience, and Enable Injections, Inc. ("Enable"), a healthcare innovation company developing and manufacturing the enFuse® On-Body Delivery System, today announced a strategic partnership naming Aptar Digital Health as Enable's preferred digital health partner for the enFuse® system. This digital solution will be designed to guide patients and caregivers throughout the injection process and help strengthen engagement support before, during and after administration. Through this partnership, Aptar Digital Health will deliver a companion digital solution
Digital solution will be designed to help guide users through injection process Aptar Digital Health, a global leader in digital health solutions enhancing the patient experience, and Enable Injections, Inc. ("Enable"), a healthcare innovation company developing and manufacturing the enFuse® On-Body Delivery System, today announced a strategic partnership naming Aptar Digital Health as Enable's preferred digital health partner for the enFuse® system. This digital solution will be designed to guide patients and caregivers throughout the injection process and help support engagement before, during, and after administration. This press release features multimedia. View the full release here
Use of Aptar Pharma's UDS Powder system supports the development of a next‑generation, virus‑agnostic nasal spray being evaluated for its potential to help protect against symptomatic viral respiratory infections AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced that its Unidose (UDS) Powder Nasal Spray System is being utilized in ENA Respiratory's Phase II clinical study of INNA 051, an investigational nasal spray being evaluated for its potential to help protect against symptomatic viral respiratory infections. This collaboration reflects the growing role of intranasal delivery technologies
This live feed shows all institutional transactions in real time.
SC 13G/A - APTARGROUP, INC. (0000896622) (Subject)
SC 13G/A - APTARGROUP, INC. (0000896622) (Subject)
SC 13G/A - APTARGROUP, INC. (0000896622) (Subject)
SC 13G/A - APTARGROUP, INC. (0000896622) (Subject)
SC 13G/A - APTARGROUP, INC. (0000896622) (Subject)
SC 13G/A - APTARGROUP, INC. (0000896622) (Subject)
SC 13G - APTARGROUP, INC. (0000896622) (Subject)
SC 13G/A - APTARGROUP, INC. (0000896622) (Subject)
SC 13G/A - APTARGROUP, INC. (0000896622) (Subject)
SC 13G/A - APTARGROUP, INC. (0000896622) (Subject)
Live finance-specific insights
AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery and consumer product dispensing, dosing and protection technologies, today reported the following first quarter results for the period ended March 31, 2026, as compared to the corresponding period of the last fiscal year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430601030/en/Aptar Reports First Quarter 2026 Results First Quarter 2026 Highlights (Compared to the prior year quarter; see Non-GAAP section for full definitions; see reconciliation for Non-GAAP measures) Reported sales increased 11% and core sales were flat Reported net income decreased 8% t
AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, including dosing and protection technologies, and consumer product dispensing, today announced that the Board declared a quarterly cash dividend of $0.48 per share. The payment date is May 27, 2026, to stockholders of record as of May 6, 2026. As previously announced, Aptar will hold a conference call on Friday, May 1, 2026, at 8:00 a.m. Central Time to discuss the Company's first quarter results for 2026. The call will last approximately one hour. Interested parties are invited to listen to a live webcast by visiting the Investors page at www.aptar.com. A replay of the conference call can also be accessed for a limited time o
AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery and consumer product dispensing, dosing and protection technologies, today reported the following fourth quarter results for the period ended December 31, 2025, as compared to the corresponding period of the last fiscal year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260205227722/en/Photo: Aptar Fourth Quarter 2025 Highlights (Compared to the prior year quarter; see Non-GAAP section for full definitions; see reconciliation for Non-GAAP measures) Reported sales increased 14% and core sales increased 5%—all three segments delivered core sales growth Reporte
AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery and consumer product dispensing, dosing and protection technologies, today announced that the Board declared a quarterly cash dividend of $0.48 per share. The payment date is February 25, 2026, to stockholders of record as of February 4, 2026. As previously announced, Aptar will hold a conference call on Friday, February 6, 2026, at 8:00 a.m. Central Time to discuss the Company's fourth quarter and year-end results for 2025. The call will last approximately one hour. Interested parties are invited to listen to a live webcast by visiting the Investors page at www.aptar.com. A replay of the conference call can also be accessed fo
AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery and consumer product dispensing, dosing and protection technologies, today announced the dates and times of quarterly conference calls for the year. Any updates to these dates or times will be communicated in subsequent press releases. Quarterly Conference Calls Press Release(1) Conference Call(2) 4th Quarter and Annual 2025 Results February 5, 2026 February 6, 2026, at 8:00 a.m. CT 1st Quarter 2026 Results April 30, 2026 May 1, 2026, at 8:00 a.m. CT 2nd Quarter 2026 Results July 30, 2026 July 31, 2026, at 8:00 a.m. CT 3rd Quarter 2026 Results
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that it has acquired Sommaplast, a specialized provider of oral dosing pharma packaging solutions, such as closures, droppers, dispensers and dosing cups, based in Brazil. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251201905597/en/Aptar Acquires Sommaplast, a Specialized Provider of Oral Dosing Pharma Packaging Solutions "Aptar has manufactured in Brazil for 25 years and this acquisition is expected to further reinforce our footprint in the region. It also helps position us to capitalize on
AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery and consumer product dosing, dispensing and protection technologies, today reported the following third quarter results for the period ended September 30, 2025, as compared to the corresponding period of the last fiscal year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251030956269/en/Aptar Reports Third Quarter 2025 Results Third Quarter 2025 Highlights (Compared to the prior year quarter; see Non-GAAP section for full definitions; see reconciliation for Non-GAAP measures) Reported sales increased 6% and core sales increased 1% Strong product volume growth
Following an increase of almost 10% a year ago AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, consumer product dosing, dispensing and protection technologies, today declared a quarterly cash dividend of $0.48 per share, an almost 7% increase from the previous dividend amount, bringing the new annualized dividend to $1.92 per share. The payment date is November 13, 2025, to stockholders of record as of October 23, 2025. Stephan B. Tanda, Aptar President and CEO, commented, "Given the strength of our business outlook, the sustained long-term growth we anticipate from our Pharma segment, and our continued strong performance across all key financial metrics, the Board of Dir
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today reported the following second quarter results for the period ended June 30, 2025, as compared to the corresponding period of the last fiscal year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250731446602/en/Aptar Reports Second Quarter 2025 Results Second Quarter 2025 Highlights (compared to the prior year quarter) Reported sales increased 6% and core sales increased 3% Reported net income increased 24% to $112 million and adjusted EBITDA increased 13% from the prior year to $218 million Rep
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today declared a quarterly cash dividend of $0.45 per share. The payment date is August 14, 2025 to stockholders of record as of July 24, 2025. As previously announced, Aptar will hold a conference call on Friday, August 1, 2025 at 8:00 a.m. Central Time to discuss the Company's second quarter results for 2025. The call will last approximately one hour. Interested parties are invited to listen to a live webcast by visiting the Investors page at www.aptar.com. Replay of the conference call can also be accessed for a limited time on the Investors page of the website. A
Live Leadership Updates
AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced that Gael Touya, a seasoned global executive with more than 30 years of experience at the company, most recently as Aptar Pharma President, has been appointed President and Chief Executive Officer, effective September 1, 2026. He will succeed Stephan B. Tanda, who has served as President and Chief Executive Officer since 2017. Stephan is expected to continue to work closely with Gael and the Board as an advisor through the end of the year to help ensure a seamless transition as the company enters its next phase of growth. Stephan intends to reti
Aptar Names Vanessa Kanu, A Finance Veteran with Over 25 Years of Experience, as Next CFO AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that Bob Kuhn, Executive Vice President and Chief Financial Officer (CFO) since 2008, has decided to retire at the end of this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240725873916/en/(Left to right) Bob Kuhn, Executive Vice President and Chief Financial Officer since 2008, has decided to retire at the end of 2024; Vanessa Kanu will become Executive Vice President and CFO on January 1, 2025,
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that Sarah Glickman, an accomplished leader with more than 30 years of global financial and operational experience, has joined its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230905451175/en/Sarah Glickman Joins Aptar's Board of Directors (Photo: Aptar) "We are pleased to welcome Sarah Glickman to our Board of Directors. Sarah's extensive knowledge of all aspects of corporate finance coupled with her global operational experience, including in the pharmaceutical industry
AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions and services, announced today that Julie Xing has joined its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230220005172/en/Julie Xing Joins Aptar's Board of Directors (Photo: Aptar) With over 20 years of experience in pharmaceutical, medtech, digital health, biotech and diagnosis, Julie's leadership approach focuses on inspiring teams to deliver sustainable growth in challenging markets and healthcare environments. With her solid track record of business transformation in multiple g
AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions and services, announced today that Matt Trerotola has joined its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220912005805/en/Matt Trerotola Joins Aptar's Board of Directors (Photo: Aptar) Matt has served as the President and Chief Executive Officer for Enovis Corporation (formerly Colfax), an innovation-driven medical technology company, since 2015. As a highly accomplished leader with over 30 years of experience, he has a distinct focus on accelerating organic growth as well as s
AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions, announced today that Candace Matthews has joined its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210524005808/en/Candace Matthews Joins Aptar Board of Directors Candace is a highly accomplished business leader with over 30 years of experience developing and marketing products for the healthcare, cosmetics, food and beverage industries. Candace currently serves as the Chief Reputation Officer for Amway, overseeing the company's global reputation strategy and brand, along with its